Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Estriol succinate vaginal gel - Italfarmaco

Drug Profile

Estriol succinate vaginal gel - Italfarmaco

Alternative Names: 6α-hydroxyestradiol; Blissel; estra-1,3,5(10)-triene-3,16α,17β-triol; Gelistrol

Latest Information Update: 07 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Italfarmaco
  • Class Estrenes; Hormonal replacements
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Atrophic vaginitis

Most Recent Events

  • 07 Dec 2022 No development reported - Phase-II for Atrophic vaginitis in Italy, Spain, Sweden, Hungary, Czech Republic (Vaginal) prior to December 2022 (NCT02967510)
  • 04 Oct 2018 Phase-III clinical trials in Atrophic vaginitis in Spain (Vaginal) (EudraCT2018-001481-42)
  • 01 May 2018 Italfarmaco completes a phase II trial for Atrophic vaginitis in Sweden, Spain, Czech Republic, Hungary and Italy (Vaginal, Gel, 0.005%, 0.002% and 0.0008%) (NCT02967510)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top